T1	Participants 15 72	HIV-infected patients with painful peripheral neuropathy:
T2	Participants 309 356	HIV-related painful peripheral neuropathy (PPN)
T3	Participants 464 475	22 patients
T4	Participants 728 843	19 patients who received at least 2 weeks of the drug, 16 of whom were crossed-over to receive the alternate agent.
